1. Home
  2. INDP vs TLPH Comparison

INDP vs TLPH Comparison

Compare INDP & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INDP
  • TLPH
  • Stock Information
  • Founded
  • INDP 2000
  • TLPH 2005
  • Country
  • INDP United States
  • TLPH United States
  • Employees
  • INDP N/A
  • TLPH N/A
  • Industry
  • INDP Biotechnology: Pharmaceutical Preparations
  • TLPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • INDP Health Care
  • TLPH Health Care
  • Exchange
  • INDP Nasdaq
  • TLPH Nasdaq
  • Market Cap
  • INDP 15.4M
  • TLPH 13.4M
  • IPO Year
  • INDP N/A
  • TLPH 2011
  • Fundamental
  • Price
  • INDP $1.27
  • TLPH $0.80
  • Analyst Decision
  • INDP Strong Buy
  • TLPH Strong Buy
  • Analyst Count
  • INDP 1
  • TLPH 2
  • Target Price
  • INDP $12.00
  • TLPH $4.50
  • AVG Volume (30 Days)
  • INDP 24.2K
  • TLPH 68.4K
  • Earning Date
  • INDP 11-04-2024
  • TLPH 11-06-2024
  • Dividend Yield
  • INDP N/A
  • TLPH N/A
  • EPS Growth
  • INDP N/A
  • TLPH N/A
  • EPS
  • INDP N/A
  • TLPH N/A
  • Revenue
  • INDP N/A
  • TLPH $398,000.00
  • Revenue This Year
  • INDP N/A
  • TLPH N/A
  • Revenue Next Year
  • INDP N/A
  • TLPH N/A
  • P/E Ratio
  • INDP N/A
  • TLPH N/A
  • Revenue Growth
  • INDP N/A
  • TLPH 57.31
  • 52 Week Low
  • INDP $1.03
  • TLPH $0.43
  • 52 Week High
  • INDP $3.25
  • TLPH $1.61
  • Technical
  • Relative Strength Index (RSI)
  • INDP 47.64
  • TLPH 43.00
  • Support Level
  • INDP $1.10
  • TLPH $0.76
  • Resistance Level
  • INDP $1.39
  • TLPH $0.83
  • Average True Range (ATR)
  • INDP 0.13
  • TLPH 0.07
  • MACD
  • INDP 0.02
  • TLPH -0.00
  • Stochastic Oscillator
  • INDP 66.67
  • TLPH 47.68

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

About TLPH Talphera Inc.

Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

Share on Social Networks: